abncov2
Vaccineexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Mar 11, 2021 (NCT04839146)
Timeline
Indications
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05329220 | Phase 3 | Aug 31, 2022 | Bavarian Nordic |
| NCT05077267 | Phase 2 | Aug 19, 2021 | Bavarian Nordic, Clinical Research Hamburg GmbH |
| NCT04839146 | Phase 1 | Mar 11, 2021 | European Union, Radboud University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bavarian Nordic | For profit | 2 | 2 | 2 | 2021 |
| Clinical Research Hamburg GmbH | For profit | 1 | 0 | 1 | 2021 |
| European Union | Government | 1 | 0 | 1 | 2021 |
| Radboud University | Academic/Hospital | 1 | 1 | 1 | 2021 |
4 organizations
Page 1 / 1